MFSD2A is a sodium-dependent lysophosphatidylcholine (LPC) symporter essential for blood-brain barrier formation and function 1. The protein specifically transports LPC-conjugated docosahexaenoic acid (DHA) across the blood-brain barrier, representing the primary mechanism by which this omega-3 fatty acid enters the brain for normal development and cognitive function 1. Structurally, MFSD2A contains a unique extracellular domain and conserved sodium-binding site that facilitates its transport mechanism 1. The transporter is specifically expressed in brain endothelial cells and plays a critical role in maintaining blood-brain barrier integrity by inhibiting transcytosis 23. Beyond brain function, MFSD2A exhibits tumor suppressor properties in various cancers, including gastric and colorectal cancer, where it suppresses proliferation, migration, and metastasis through multiple pathways including S100A14/STAT3 signaling 45. In diabetic retinopathy, reduced MFSD2A expression contributes to vascular dysfunction, and its overexpression combined with DHA supplementation shows therapeutic potential 6. MFSD2A mutations cause microcephaly syndromes, highlighting its essential role in neurodevelopment 1. The protein's dual functions in lipid transport and blood-brain barrier regulation make it an attractive target for therapeutic modulation.